Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PerkinElmer To Buy UK-Based Immunodiagnostics For $155M

Executive Summary

PerkinElmer will add chemiluminescence products in endocrinology, autoimmunity and diagnostics to its portfolio with the planned buyout of Immunodiagnostics.

You may also be interested in...



Labcorp Buys Myriad Genetics’ Vectra Autoimmune Test Business

Labcorp has agreed to pay $150m in cash for Myriad Genetics’ autoimmune business, one of three major units Myriad is unloading as it tries to narrow its focus to oncology, women's health and mental health diagnostics.

Hologic Continues 2021 Spending Spree With $795M Acquisition Of Mobidiag

Mobidiag develops molecular diagnostic tests and instrumentation that will expand Hologic’s acute care testing capabilities.

PerkinElmer Adds Infectious Disease Testing By Acquiring Oxford Immunotec For $591M

PerkinElmer’s sales and testing capacity will expand the reach of Oxford Immunotec’s proprietary interferon gamma release tuberculosis assay technology.

Topics

Related Companies

UsernamePublicRestriction

Register

MT143936

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel